Skip to main content

Table 5 Demographic and clinical characteristics of patients with SLE and PAH by NYHA functional classes I/II and III/IV

From: Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients

  NYHA class I/II n = 9 NYHA class III/IV n = 12 P-value
Female sex, n (%) 9 (100) 11 (91.7) 0.375
Age at SLE diagnosis 26.7 ± 10.9 30.3 ± 9.9 0.219
Age at PAH diagnosis 35.8 ± 11.7 35.3 ± 12.3 0.922
SLE length at PAH diagnosis 9.1 ± 7.5 4.9 ± 4.9 0.138
Smoking, n (%) 1 (11) 0 (0) 0.352
Miscarriage, n (%) 3 (33) 3 (25) 0.676
Pregnancy, n (%) 6 (66.7) 8 (66.7) 1.000
Raynaud’s phenomenon, n (%) 7 (77.8) 10 (81) 0.748
Livedo reticularis, n (%) 1 (11.1) 0 (0) 0.237
Arterial thrombosis, n (%) 0 (0) 1 (8.3) 0.375
Venous thrombosis, n (%) 4 (44.4) 1 (8.3) 0.055
Anti-SM, n (%) 2 (25) 2 (22.2) 0.893
Anti-RNP, n (%) 4 (50) 7 (77.8) 0.232
Anti-Ro, n (%) 2 (25) 3 (33.3) 0.707
Anti-La, n (%) 0 (0) 2 (22.2) 0.156
Positive anti- aCL IgM, n (%) 1 (12.5) 1 (10) 0.867
Positive anti- aCL IgG, n (%) 1 (12.5) 2 (20) 0.671
Positive anti-dsDNA, n (%) 2 (25) 1 (11.1) 0.453
C2 (mg/dL) 85.2 ± 34.3 88.1 ± 28.6 0.859
CH100 (mg/dL) 83.8 ± 30.2 93.1 ± 31.4 0.579
CRP (mg/dL) 3.43 ± 2.01 19.20 ± 50.20 1.000
SLEDAI 2 ± 4.5 3.0 ± 3.4 0.299
6-min walk test 413 ± 14.8 417.7 ± 92.9 0.934
FVC (%) 84.1 ± 17.5 75.7 ± 13.2 0.143
Dco (%) 52.2 ± 8.3 44.5 ± 23.2 0.548
Death, n (%) 1 (11.1) 5 (41.7) 0.125
Nailfold capillaroscopy
 SD pattern, n (%) 4 (66.7) 5 (50) 0.515
 Normal or unspecific 2 (33.3) 5 (50)  
RHC
 MPAP 47.6 ± 7.7 50.0 ± 14.6 0.654
 CI 2.61 ± 0.66 2.36 ± 0.75 0.441
 PVRI 8.86 ± 3.0 12.62 ± 11.47 0.824
Treatment
 Sildenafil, n (%) 4 (44.4) 8 (67) 0.309
 Bosentan, n (%) 5 (55.6) 5 (41.7) 0.528
 Cyclophosphamide IV, n (%) 4 (44.4) 6 (50) 0.801
 Methylprednisolone IV, n (%) 3 (33.3) 5 (41.7) 0.697
 Oral anticoagulants, n (%) 6 (66.7) 7 (63.6) 0.642
  1. Data are expressed as the mean ± standard deviation or n (%). SLE systemic lupus erythematosus, PAH pulmonary arterial hypertension, anti-aCL anticardiolipin, CI cardiac index, CRP C-reactive protein, Dco carbon monoxide diffusing capacity, FVC forced vital capacity, IV intravenous, MPAP mean pulmonary artery pressure, NYHA New York Heart Association, PVRI pulmonary vascular resistance index, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index